Kyverna Therapeutics is making significant strides in the development of a groundbreaking treatment for Stiff-Person Syndrome (SPS), a debilitating autoimmune neurological disorder. New data from their pivotal Phase III KYSA-8 trial reveals sustained, meaningful improvements in patients treated with miv-cel (mivocabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T) therapy. These compelling results, particularly the sustained benefit observed over a year, position miv-cel as a frontrunner for FDA approval and could represent the first-ever approved drug specifically for SPS, a condition with a profound unmet medical need.
n
Main Facts: A Beacon of Hope in the Absence of Approved Therapies
n
The latest findings from Kyverna’s KYSA-8 study, a registrational trial (NCT06588491), have demonstrated remarkable sustained efficacy of miv-cel in patients suffering from Stiff-Person Syndrome. At 12 months post-treatment, patients experienced a significant 49% improvement in the timed 25-Foot Walk (T25FW), a key measure of mobility and disease severity. This sustained improvement builds upon the already impressive 46% benefit observed at week 16, indicating the long-lasting impact of the single-dose CAR-T therapy.
n
Crucially, more than a third of the trial participants were able to complete the T25FW in under 5 seconds, a benchmark comparable to the walking speed of healthy adults. This level of functional recovery is unprecedented in the context of SPS, a condition characterized by severe muscle stiffness, rigidity, and painful spasms that progressively impair mobility and quality of life. The data further underscores the durability of the treatment, with 95% of patients who achieved a clinically meaningful improvement at the primary analysis maintaining their gains at the 12-month mark.
n
The safety profile of miv-cel in the KYSA-8 trial also continues to be highly encouraging. The anti-CD19 CAR-T therapy, which leverages CD28 co-stimulation, was well-tolerated, with no instances of high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Furthermore, no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were reported. These findings are critical, as managing potential toxicities is paramount in the development of novel cell therapies.
n
These positive outcomes were initially presented and confirmed at the American Academy of Neurology (AAN) Annual Meeting in April 2026, where Kyverna announced that the study had met both its primary and secondary endpoints after 16 weeks of treatment. The subsequent one-year data provides even greater confidence in the therapeutic potential of miv-cel.
n
Chronology of Progress: From Initial Promise to Sustained Efficacy
n
The journey of miv-cel for SPS has been marked by steady progress and increasingly positive data readouts. The KYSA-8 trial represents the culmination of years of research and development in leveraging CAR-T technology for autoimmune diseases.
n
- n
- Early Phase Trials: While specific details of earlier phase trials are not elaborated in the provided text, the progression to a Phase III registrational study signifies strong preclinical and early clinical evidence supporting miv-cel’s efficacy and safety in SPS.
- AAN Annual Meeting (April 2026): Kyverna Therapeutics officially announced that the KYSA-8 study had met its primary and secondary endpoints at the 16-week mark, signaling a significant breakthrough in the treatment of SPS. This announcement generated considerable excitement within the medical and patient communities.
- Presentation of 12-Month Sustained Efficacy Data: The recent release of one-year data from the KYSA-8 trial has further solidified the promise of miv-cel. This data demonstrates that the initial benefits observed are not transient but are sustained over an extended period, offering a glimmer of long-term hope for patients.
- Rolling BLA Submission to FDA: Armed with this compelling one-year data, Kyverna is now poised to incorporate these findings into its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). This submission marks a crucial step towards seeking regulatory approval for miv-cel as a treatment for SPS.
n
n
n
n
n
The consistent positive trajectory of the KYSA-8 trial underscores Kyverna’s commitment to advancing this therapy through rigorous clinical evaluation.
n
Supporting Data: Quantifying the Impact on Patient Lives
n
The clinical data from the KYSA-8 trial provides concrete evidence of miv-cel’s profound impact on patients with SPS:
n
- n
- Timed 25-Foot Walk (T25FW) Improvement:n
- n
- Week 16: 46% improvement in T25FW.
- Month 12: Sustained 49% improvement in T25FW. This increase, though seemingly modest, signifies that the positive effects are not only maintained but potentially continue to improve or stabilize at a higher level of functional recovery.
n
n
- Achieving Healthy Adult Walking Speeds: Over one-third of patients achieved a T25FW of less than 5 seconds, a speed indicative of a healthy adult’s gait. This is a critical benchmark for functional independence and quality of life.
- Sustained Benefit: 95% of patients who experienced a clinically meaningful improvement at the primary analysis maintained their gains at the 12-month follow-up. This high rate of sustained benefit is a testament to the potential for miv-cel to offer long-term relief from the debilitating symptoms of SPS.
- Safety Profile:n
- n
- No high-grade Cytokine Release Syndrome (CRS).
- No Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
- No Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).
These safety findings are highly reassuring and crucial for regulatory approval, especially given the complexity of CAR-T therapies.
n
n
n
n
n
The significance of these quantitative improvements cannot be overstated. For individuals with SPS, even small gains in mobility and reductions in stiffness can translate to substantial improvements in their ability to perform daily activities, reduce pain, and regain a sense of independence.
Official Responses: Expert Opinions and Patient Advocacy
The clinical trial results have garnered significant attention from leading experts in the field of autoimmune neurology. Dr. Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine and lead investigator of the KYSA-8 trial, expressed strong optimism regarding the findings:
“The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies. After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS.”
Dr. Piquet’s statement highlights the critical unmet need in SPS and the transformative potential of miv-cel. The fact that a single dose can lead to such sustained improvements is a key differentiator and a significant advantage in treating a chronic and progressive condition.
The public profile of SPS has also been raised in recent years, notably with the diagnosis of the iconic singer Céline Dion in 2022. This has brought increased awareness to the challenges faced by individuals living with this rare disorder and has amplified the urgency for effective treatments. The prospect of a first-in-class therapy like miv-cel offers immense hope to patients and their families.
Implications: A Paradigm Shift in Autoimmune Disease Treatment
The potential approval of miv-cel for Stiff-Person Syndrome carries profound implications, not only for SPS patients but also for the broader landscape of autoimmune disease treatment:
- First-to-Market Advantage: Kyverna Therapeutics is on the cusp of achieving a significant first-to-market advantage. Currently, there are no FDA-approved drugs specifically for SPS. This means that miv-cel could become the sole therapeutic option for a condition that causes immense suffering, offering a lifeline to those who have few or no treatment choices.
- Validation of CAR-T for Autoimmunity: The success of miv-cel in SPS would further validate the use of CAR-T therapy, a modality traditionally associated with hematological malignancies, for treating complex autoimmune disorders. This could pave the way for similar CAR-T approaches to be explored and developed for a wider range of autoimmune conditions, potentially revolutionizing their management.
- Addressing a Rare Disease Gap: Stiff-Person Syndrome is a rare disease, and the development of therapies for such conditions often faces significant hurdles. Kyverna’s progress demonstrates a successful pathway for bringing innovative treatments to underserved patient populations. The sparse drug pipeline for SPS further amplifies the importance of miv-cel’s advancement.
- Impact on Other Autoimmune Diseases: Kyverna is also pursuing miv-cel for other autoimmune conditions, including generalized myasthenia gravis (gMG). Recent data from the Phase II/III KYSA-6 study in gMG also shows promising sustained improvements. If successful, this dual application could broaden the impact of miv-cel and solidify Kyverna’s position as a leader in autoimmune CAR-T therapy. The projected growth of the gMG market, expected to reach $13 billion by 2034, further highlights the significant commercial and therapeutic potential of these CAR-T therapies.
- Potential for Disease Modification: The sustained efficacy observed with miv-cel suggests that it may not just be a symptomatic treatment but could potentially modify the underlying autoimmune process driving SPS. This would represent a significant paradigm shift from current management strategies, which often focus on symptom relief and immune suppression with limited long-term impact.
- Inspiration for Future Research: The promising results of miv-cel will undoubtedly inspire further research and investment into novel therapeutic strategies for SPS and other rare autoimmune diseases. This could accelerate the discovery and development of even more effective and targeted treatments in the future.
In conclusion, the sustained efficacy and favorable safety profile demonstrated by miv-cel in the KYSA-8 trial represent a monumental step forward in the fight against Stiff-Person Syndrome. As Kyverna Therapeutics moves towards its BLA submission, the prospect of a first-approved therapy for SPS is closer than ever, offering a profound sense of hope and a potential transformation in the lives of those affected by this devastating condition. The success of miv-cel could also herald a new era in the treatment of autoimmune diseases, with CAR-T therapy emerging as a powerful tool in the physician’s arsenal.
